Bromoform
CASRN 75-25-2
- IRIS Summary (PDF) (23 pp, 152 K)
- Status: Bromoform is not being reassessed by IRIS at this time.
Health Hazard Assessments for Effects Other than Cancer
Reference Dose for Oral Exposure (RfD) (PDF) (23 pp, 152 K)
last updated: 09/30/1987
|
Reference Concentration for Inhalation Exposure (RfC) (PDF) (23 pp, 152 K)
last updated: 12/01/1993
Information reviewed but value not estimated.
Cancer Assessment
Weight of Evidence for Cancer (PDF) (23 pp, 152 K)
last updated: 09/01/1990
| WOE Characterization | Framework for WOE Characterization |
|---|---|
| B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (US EPA, 1986) |
- Based on inadequate human data and sufficient evidence of carcinogenicity in animals, namely an increased incidence of tumors after oral administration of bromoform in rats and intraperitoneal administration in mice. Bromoform is genotoxic in several assay systems. Also, bromoform is structurally related to other trihalomethanes (e.g., chloroform, bromodichloromethane, dibromochloromethane) which have been verified as either probable or possible carcinogens.
- This may be a synopsis of the full weight-of-evidence narrative.
Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (23 pp, 152 K)
Oral Slope Factor:
7.9 x10 -3 per mg/kg-day
Drinking Water Unit Risk:
2.3 x10 -7 per µg/L
Extrapolation Method:
Linearized multistage procedure, extra risk
Tumor site(s): Gastrointestinal
Tumor type(s): Neoplastic lesions in the large intestine (NTP, 1988)
Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (23 pp, 152 K)
Inhalation Unit Risk:
1.1 x10 -6 per µg/m3
Extrapolation Method:
Linearized multistage procedure, extra risk
Tumor site(s): Gastrointestinal
Tumor type(s): Neoplastic lesions in the large intestine (NTP, 1988)
You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.
